Multidrug-resistant Tuberculosis Management in Resource-limited Settings
Eva Nathanson*
, Catharina Lambregts-van Weezenbeek†, Michael Rich‡, Rajesh Gupta*, Jaime Bayona‡§, Kai Blöndal†, José A. Caminero¶, J. Peter Cegielski#, Manfred Danilovits**, Marcos A. Espinal*, Vahur Hollo††, Ernesto Jaramillo*, Vaira Leimane‡‡, Carole D. Mitnick§§, Joia S. Mukherjee§§, Paul Nunn*, Alexander Pasechnikov‡¶¶, Thelma E. Tupasi##, Charles Wells#, and Mario C. Raviglione*
Author affiliations: *World Health Organization, Geneva, Switzerland; †KNCV Tuberculosis Foundation, The Hague, the Netherlands; ‡Partners In Health, Boston, Massachusetts, USA; §Socios En Salud, Lima, Peru; ¶International Union Against Tuberculosis and Lung Disease, Paris, France; #Centers for Disease Control and Prevention, Atlanta, Georgia, USA; **Tartu University Clinics, Tartu, Estonia; ††National TB Programme, Tallinn, Estonia; ‡‡State Centre of Tuberculosis and Lung Diseases of Latvia, Riga, Latvia; §§Harvard Medical School, Boston, Massachusetts, USA; ¶¶MDR-TB Project in Tomsk Oblast, Tomsk, Russian Federation; ##Makati Medical Center, Makati, the Philippines
Main Article
Figure 1
Figure 1. Treatment outcomes of multidrug-resistant tuberculosis patients in Estonia (46 patients), Latvia (245 patients), Lima (508 patients), Manila (105 patients), and Tomsk (143 patients).
Main Article
Page created: November 17, 2011
Page updated: November 17, 2011
Page reviewed: November 17, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.